Clinical trial
A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Dazodalibep in Participants With Sjögren's Syndrome With Moderate-to-severe Systemic Disease Activity
NCT06104124 is registered in ClinicalTrials.gov with Amgen as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Dazodalibep in Participants With Sjögren's Syndrome With Moderate-to-severe Systemic Disease Activity
- Lead sponsor
- Amgen
- Phase
- Phase 3
- Overall status
- Completed
- Start date
- January 24, 2024
- Completion date
- August 17, 2026
- Enrollment
- 651 (actual)
- Sites
- 206
Conditions
As the registry lists them; a condition with its own page is linked.